Replimune Group针对非小细胞肺癌（Non-melanoma (NMSC) / Non-small cell lung cancer NSCLC)）适应症的RP1 (vusolimogene oderparepvec) and OPDIVO (nivolumab) - (IGNYTE)管线完成Phase 1/2临床试验

动脉智库 2023-09-22 02:14





微信扫码分享